Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Amylin Analogs Market size was valued at USD 1.4 billion in 2024 and is projected to reach USD 4.4 billion by the end of 2037, rising at a CAGR of 10.2% during the forecast period, i.e., 2025 to 2037. In 2025, the industry size of amylin analogs is assessed at USD 1.6 billion.
The international patient pool in the amylin analogs market is substantial, which is highly attributed to a rise in obesity and diabetes prevalence. In this regard, an article was published by the World Health Organization (WHO) in 2024, demonstrating that more than 545 million elders suffered from diabetes in 2024. This, however, is projected to exceed 785 million by the end of 2045. Likewise, approximately 1.5 million people suffer from obesity globally, eventually resulting in a huge need for metabolic therapies such as amylin analogs. Besides, the supply chain system for these medications includes active pharmaceutical ingredient (API) manufacturers from Europe, China, and India, catering to almost 62% of the production, thus making it suitable for market growth.
Furthermore, the amylin analogs market is also boosted by the trade dynamics, readily dominated by the EU and the U.S. imports from Asia, of which China exports approximately 45% of peptide APIs internationally. In addition, the U.S. imported USD 2.9 billion of obesity and diabetes-based drugs in 2024, and the EU catered to importing USD 2.1 billion. Besides, the aspect of funding for research, deployment, and development for the market has also increased, with the provision of USD 3.3 billion by the NIH for research in metabolic disorders. Likewise, the Europe Commission allocated €1.5 billion to initiate innovation for obesity and diabetes drugs under Horizon Europe, thereby effectively driving market expansion.
Amylin Analogs Sector: Growth Drivers and Challenges
Growth Drivers
- Intervention and improvement in healthcare quality: The amylin analogs market is positively influenced by evidence-specific medical quality improvements. As per the 2022 AHRQ clinical study, early intervention with these drugs is intended to diminish diabetes-based hospitalizations by almost 24%, saving USD 1.9 billion in the U.S. healthcare expenses within two years. Owing to this, amylin analogs are regarded as cost-efficient solutions for buyers seeking to combat long-term complications, thereby denoting a positive impact on the overall market scenario internationally.
- Administrative spending trends: The aspect of government healthcare expenditure is a crucial driving factor for the amylin analogs market. For instance, Medicare spending on amylin analogs reached USD 955 million in 2023, constituting a 17% yearly increase facilitated by Part D coverage expansions. Additionally, this growth caters to CMS’s metabolic therapies prioritization amidst the surge in diabetes occurrence. Besides, an increase in out-of-pocket expenses, accounting for USD 1,250 per year, developed disparity in accessibility for uninsured populations, thus constituting an optimistic market outlook.
Key Manufacturer Strategies Driving Amylin Analogs Market Expansion
Leading manufacturers across different nations are continuously deploying three major strategies to dominate the overall amylin analogs market. These include expansion in market accessibility, tactical partnerships, along with pipeline innovation. For instance, in 2024, Zealand Pharma undertook the Asia licensing, which has reduced price strategies by almost 42% in India. Besides. In 2023, Eli Lily proposed a deal with the NIH to escalate oral amylin production by capturing 13% of diabetes-based research and development grants. Meanwhile, the FDA-approved cagrilintide-semaglutide combo unveiled by Novo Nordisk is projected to target more than USD 5.5 billion in obesity by 2030, thereby propelling the international market development.
Revenue Opportunities for Manufacturers (2023–2025)
|
Company |
Strategy |
Revenue Impact |
Market Share Change |
|---|---|---|---|
|
Novo Nordisk |
Cagrilintide obesity launch |
+USD 1.6 billion (2025) |
+8.2% (2023–25) |
|
Eli Lilly |
Oral amylin R&D |
USD 325 million NIH grants (2024) |
+5.3% pipeline dominance |
|
Zealand Pharma |
Asia distribution partnerships |
40.5% price reduction in India |
3x volume growth |
|
AstraZeneca |
Medicare Part D lobbying |
USD 635 million additional coverage (2024) |
+13.6% U.S. access |
Key Feasible Expansion Models Shaping the Amylin Analogs Market
The amylin analogs market is gaining exposure in emerging markets, which is attributed mainly to three major models. These include a tiered form of pricing, localized production processes, and private-public partnerships. For instance, Novo Nordisk effectively collaborated with the NHM in India to subsidize cagrilintide by diminishing costs by almost 39%. Besides, in 2024, the API plant in India reduced import reliance by 60% owing to the USD 250 million fund provision by Eli Lilly. Likewise, Zealand Pharma readily implemented the WHO’s equitable pricing framework to bolster accessibility across 16 LMICs, thereby suitable for market upliftment.
Feasibility Models for Market Expansion (2023–2025)
|
Model |
Region |
Outcome |
Revenue Impact |
|---|---|---|---|
|
PPP with NHM (Novo) |
India |
39% cost reduction |
+USD 135 million (2024) |
|
Local API production (Lilly) |
India |
60% import substitution |
+USD 90 million annual savings |
|
Tiered pricing (Zealand) |
Africa |
16 LMIC market entries |
+USD 70 million (2025) |
Challenges
- Barriers in emerging market facilities: The existence of developing nations comprises unique challenges, owing to limited healthcare systems that negatively impact the amylin analogs market. For instance, according to the 2024 WHO AFRO report, less than 11% of clinics in Africa are able to perform diagnostic tests. Besides, India comprises gaps in the pharmaceutical cold chain system, wherein an estimated 35% of pharmacies improperly store temperature-specific peptides. However, these limitations require manufacturers to initiate parallel investments to cater to drug development and restore market expansion.
- Threats in biosimilar and patent cliffs: The aspect of limited patient protection effectively poses revenue risks for innovators in the amylin analogs market internationally. For instance, Novo Nordisk is projected to experience a USD 1.6 billion revenue exposure during the core patent expiry of cagrilintide, with approximately four biosimilar developers initiating preclinical trials. Besides, in 2023, Eli Lilly invested USD 85 million in defending pramlintide patents against challengers, which reflected an intense competition in the obesity and diabetes space. Therefore, all these challenges effectively limit the growth and expansion of the market globally.
Amylin Analogs Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
10.2% |
|
Base Year Market Size (2024) |
USD 1.4 billion |
|
Forecast Year Market Size (2037) |
USD 4.4 billion |
|
Regional Scope |
|
Amylin Analogs Segmentation
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
Based on distribution channel, the hospital pharmacies segment is projected to hold the largest share of 58.2% in the amylin analogs market by the end of 2037. The segment’s growth is highly propelled by its pivotal role in distributing specialty drugs and catering to inpatient obesity and diabetes care services. As per an article published by the CMS in 2024, an estimated 80% of Medicare-covered amylin prescriptions are dispensed through hospital-based pharmacies, owing to integrated care pathways, bulk purchase power, and complicated administration. For instance, an estimated 65% of hospitals in the U.S. comprise metabolic specialty clinics that can effectively stock amylin therapies.
Product Type (Cagrilintide, Pramlintide)
Based on product type, the cagrilintide segment is anticipated to hold the second-largest share of 43.7% in the amylin analogs market during the forecast period. This growth readily originates from robust clinical adoption, along with superior efficacy in obesity management. As per the 2024 FDA-based clinical trial data report, cagrilintide demonstrated 18% to 22% of sustained weight reduction, which significantly outperformed old analogs, including pramlintide by 6% to 8%. In addition, its dual-action mechanism in the form of a GLP-1/amylin receptor agonist makes it a preferable choice for combination therapies, especially in the case of obesity-based type 2 diabetes.
Our in-depth analysis of the amylin analogs market includes the following segments:
|
Distribution Channel |
|
|
Product Type |
|
|
Application |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportAmylin Analogs Industry - Regional Synopsis
North America Market Analysis
North America in the amylin analogs market is projected to account for the highest share of 51.9% during the forecast timeline. The market’s growth in the region is propelled by the presence and availability of strong medical spending as well as a rise in obesity rates. For instance, as stated in the CDC report, approximately 44% of the adult population in the U.S. readily suffers from obesity disorders. Besides, the U.S. effectively dominates the region with 95% of the overall regional demand, attributed to expansion in insurance coverage and the adoption of private insurers. Also, Canada caters to 15% of the regional revenue due to administrative controls and provincial formulary additions.
The amylin analogs market in the U.S. is readily dominating the region with a revenue share of 49.5%, mainly due to the obesity epidemic. Besides, the aspect of federal funding has reached USD 5.5 billion in 2024, of which 10% is allocated for diabetes. On the other hand, Medicare spending increased by 17% on a year-over-year (YoY) basis and reached the USD 850 million mark. Moreover, a private insurer provides 90% coverage of cagrilintide scripts that result in AHRQ-driven cost savings. Also, hospital-centric distribution along with combination therapies are other trends that are proactively amplifying the market in the country.
The amylin analogs market in Canada is continuously growing at a rate of 9.1%, which is attributed to the existence of provincial healthcare investments. For instance, between 2021 and 2024, there has been a surge in overall healthcare spending by 18.5% in Ontario, which positively impacts the market growth in the country. Besides, the country also comprises a federal provision of USD 3.4 billion, of which an estimated 8.8% is allocated for the health and medical budget. Meanwhile, there are other factors, including the presence of cold chain gaps, along with price regulations, that positively contribute to market upliftment.
Europe Regional Market Size & Growth
Europe in the amylin analogs market is expected to account for a considerable share of 29.5% by the end of the forecast duration. According to the 2024 ECDC report, an estimated 25% of the adult population in the region is readily affected by obesity. In addition, the region also constitutes streamlined administrative acceptances through the EMA PRIME scheme that positively influences the market upliftment. Besides, Germany has been deliberately leading with a 13% growth rate since 2021, along with €5 billion in spending in 2024. Meanwhile, the UK caters to 8.5% of the regional healthcare budget, thus denoting a positive outlook for market growth.
The amylin analogs market in Germany is projected to capture 37% of the overall regional revenue by the end of 2037. This is effectively driven by the presence of an efficient reimbursement system and a surge in the occurrence of obesity. Besides these factors, the country has made an expenditure of €7 billion on amylin therapies in 2024, of which 14% yearly growth is fueled by the value-based pricing model of the AMNOG. Moreover, over 75% of regional hospitals currently stock cagrilintide, owing to the availability of G-BA mandates for metabolic care services, thus suitable for market growth in the country.
The amylin analogs market in the UK is projected to hold 27% of the regional revenue during the forecast period. This upliftment is mainly driven by the 9% of the budget allocation by the NHS. In addition, the acceptance of cagrilintide for BMI>35 by NICE in 2024 also deliberately triggered 16% of the demand growth. Also, the Brexit-specified API limitation has increased costs by 12%, thereby positively catering to the market development in the country. Meanwhile, the centralized procurement initiative by the NHS has secured a 16% discount, while research and development incentives aimed to bolster the localized production, thus creating an optimistic outlook for the market.
Companies Dominating the Amylin Analogs Landscape
- Novo Nordisk
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Eli Lilly
- Zealand Pharma
- Sanofi
- AstraZeneca
- Merck & Co.
- Boehringer Ingelheim
- Pfizer
- Amgen
- Takeda Switzerland
- Biocon
- Dr. Reddy’s
- Hetero Drugs
- Prosidion
- Hanmi Pharma
The international amylin analogs market is readily dominated by key players, including Novo Nordisk, accounting for 36% of the global share, and Eli Lilly, accounting for 27% of the share. Both these organizations have leveraged their diabetes as well as obesity portfolios, thereby catering to market upliftment on a worldwide basis. Besides, Sanofi and Zealand Pharma both have readily focused on combination therapies. Meanwhile, organizations in India, such as Dr. Reddy’s and Biocon, have readily targeted biosimilars, thus a prolific opportunity for market upliftment on the international scenario.
Here is a list of key players operating in the global market:
Recent Developments
- In June 2024, Eli Lilly and Company made an investment of USD 1.9 billion for the latest peptide manufacturing plant in Research Triangle Park, intending to manufacture oral amylin analogs.
- In April 2024, Zealand Pharma A/S entered into a partnership with Boehringer Ingelheim to produce next-generation amylin/GLP-1 dual agonists, which is possible with an upfront expense of USD 575 million.
Author Credits: Radhika Pawar
- Report ID: 7710
- Published Date: Jun 03, 2025
- Report Format: PDF, PPT
